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The Dendritic Cell Therapy for Oncology Roundtable Conference was organized by Reliable Cancer Therapies and
moderated by Prof. Dr. Steven De Vleeschouwer. The organizer, Reliable Cancer Therapies, is a Swiss non-profit
organization that provides information on evidence-based cancer treatments and funding for the development of
a selection of promising cancer therapies. In order to be able to give valuable information about dendritic cell (DC)
therapy to patients and physicians, the organizing committee felt it necessary to organize this conference to get
an up-to-date status of the academic DC therapy field, collect ideas to guide patients towards clinical trials and to
induce cross-fertilization for protocol optimization. In total, 31 experts participated to an in-depth discussion about
the status and the future development path for dendritic cell vaccines. The conference started with general
presentations about cancer immunotherapy, followed by comprehensive overview presentations about the
progress in DC vaccine development achieved by each speaker. At the end of the meeting, a thorough general
discussion focused on key questions about what is needed to improve DC vaccines. This report does not cover all
presentations, but aims to highlight selected points of interest, particularly relating to possible limitations and
potential approaches to improvement of DC therapies specifically, and also immunotherapeutic interventions in
general terms.
General topics of cancer vaccination
The conference started with an introductory lecture by
Chris Schmidt, addressing key aspects why cancer
vaccines do not work as expected. Initially, cancer vac-
cines were tested in the systemic disease setting and
after obtaining positive results in this patient population,
moved to the minimal residual disease (MRD) setting
because of the hypothesis that if a vaccine worked in a
macroscopic disease setting, it should work better in the
MRD setting (less immunosuppression). However, in the
MRD setting adjuvant vaccines have often failed, which
may be due to too short follow-up periods. On the
other hand, it could also be postulated that the systemic
disease setting just indicates the availability of large
amounts of antigen, where the vaccine can trigger an
anti-vaccine T cell response that attack the tumor and
in this way activate a second wave of anti-tumor CTL.
This relates to the vaccine targets: a meta-analysis of all
immunotherapy trials indicated that the rate of objective
clinical responses is higher when undefined antigens are
used as compared to defined antigens [1,2]. This argues
that many targets need to be attacked but that till now:
(1) we do not know which are the relevant targets; or
(2) other molecules are present in tumor extracts that
influence the regulatory environment in a way that
defined antigens cannot; or (3) effective immune
responses only act at sites of macroscopic tumor.
Another reason why cancer treatments in general and
vaccines in specific fail to cure patients could be related
to the issue of timing of therapy. This was addressed by
Brendon Coventry, who presented data indicating that
the endogenous anti-tumor immune response follows a
cyclical pattern (measured by CRP) which is dependent
on antigen persistence and that this cycle could likely
potentially correlate with numbers of effector T cells
and regulatory T cells (Treg) over time. Preliminary evi-
dence suggests that efficacy of chemo-, radio- or immu-
notherapy could be boosted by appropriate timing to
putative ‘therapeutic windows’ in the individual patient’s
CRP cycle [3]. Furthermore, cancer vaccines do not
encounter a naïve environment, but instead need to
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counter tumor-induced tolerogenic mechanisms. Treg
are major players in immunosuppression, but in humans
there are controversies as to the exact phenotype of
these cells. Increased percentages of Treg have been
described in various malignancies, but it is also impor-
tant to take into account that absolute lymphocyte
counts and percentage of CD4+ T cells are also abnor-
mal in cancer patients. Therefore, it is necessary to mea-
sure absolute numbers of Treg in blood instead of
percentages. To date however, no regimen is available to
reproducibly deplete Treg before proceeding to cancer
vaccination. This could be due to the fact that we are
looking at total Treg, which may not all be functional?
This urges us to focus on identifying functional Treg.
To this regard, Michael Quinn presented results about
TNFRII+ Treg, which express higher levels of FoxP3
than conventional Treg, express CCR4 (migration to
tumor) and CCR7 (migration to lymph nodes -interferes
with priming of anti-tumor responses). Furthermore,
preliminary results indicated that although total Treg
levels increase during chemotherapy, TNFRII+ Treg are
selectively depleted by chemotherapy and the remaining
TNFRII+ Treg express lower levels of FoxP3, that have
a reduced suppressive capacity.
Feasibility and safety of DC vaccination in cancer
patients
Most clinical trials conducted to date with DC vaccines
are phase I feasibility studies. Despite many alterations
in the immune system of cancer patients, all presenters
reported that it was feasible to generate the desired
numbers of DC to complete the planned vaccination
scheme in most patients. However, Allan Dietz pointed
out that we need to cautiously report the characteristics
of the generated DC, because the phenotype of DC in
trials is consistently different than in preclinical studies
with normal donors. This deficiency in DC differentia-
tion in tumor bearing patients is independent of tumor
type and maturation method and there appear to be
tumor-specific conditions for optimal maturation of DC.
In most of the presented studies, DC vaccination was
safe, well tolerated, with minimal side effects. However,
Dagmar Marx and Stefaan Van Gool reported the occur-
rence of some grade III/IV adverse events in a minority
of patients, but this could possibly be related to disease
localization in the brain (both studies in brain tumors)
[4,5]. Some participants reported the induction of
auto-immune effects like vitiligo, but in general most par-
ticipants agreed that some degree of auto-immunity is
probably beneficial for DC vaccine efficacy.
Patient selection
As outlined above, it was originally hypothesized that
DC vaccines should perform better in the MRD setting
as compared to patients with widespread disease. How-
ever, this does not always appear to be the case, which
is possibly due to the altered immune system in cancer
patients and the high degree of immunosuppression.
Therefore, it would be ideal if we could select patients
that are likely to benefit from DC vaccination. To this
regard, Angus Dalgleish reported on a study where pre-
vaccine sera from responders and non-responders were
compared. This led to the identification of molecules
that can distinguish responder patients from the non-
responder group with 67% sensitivity and 100% specifi-
city. All identified molecules are pro-inflammatory and
are increased in the non-responder population; however,
no details were given about the exact nature of these
molecules. Bart Neyns reported that baseline CRP, LDH,
and WHO performance status can also identify mela-
noma patients likely to benefit from DC vaccinations.
Chris Schmidt showed that low S-100B predicts
response to treatment in melanoma. Allan Dietz pre-
sented data showing that suppressive monocytes are
increased in several malignancies and these cells mediate
a global immune paralysis. Suppressive monocytes were
found to be prognostic for cancer survival independent
of therapy [6,7]. Selection of patients on the basis of the
CRP inflammatory cycle was also raised by Brendon
Coventry as a possibility for patient selection with
respect to timing of administration and targeting
of therapy, in order to induce the desired immune
response.
Clinical effects of DC vaccines
Clinical responses are of course largely affected by the
setting in which vaccination occurs (measurable disease
versus MRD), the type of cancer and the life expectancy
of the patients. Furthermore, the evaluation of clinical
efficacy can be impeded by the application of concurrent
or subsequent therapeutic regimens. Moreover, most
trials conducted to date are phase I clinical trials in
which clinical efficacy is very difficult to assess. Never-
theless some promising results have been obtained. In
general, long-term objective responses (CR or PR) are
observed in a minority of patients, while a greater pro-
portion of patients presents with disease stabilization. In
particular, Bart Neyns pointed out that stabilization is
often followed by disease regression and that clinical
responses could be delayed even up to several months
after initiation of treatment, indicating an immune-
related response pattern (as described for anti-CTLA4
therapy). Therefore, immune-related response criteria
(irRC) may be more relevant than RECIST/WHO cri-
teria for the assessment of anti-tumor activity [8,9].
Furthermore, most participants agree that long-term dis-
ease stabilization resulting in prolonged survival is also
a relevant clinical outcome, which is of benefit for
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patients. The typical slow response pattern observed also
indicates that DC vaccination is no option for patients
with rapidly progressing disease and that patient selec-
tion is critical.
Immune response monitoring after
immunotherapy
The rationale behind DC-based immunotherapy is that
injected DC will induce a tumor-specific immune
response resulting in tumor shrinkage/clearance. So, ide-
ally we should be able to identify patients that respond
to therapy by analyzing the anti-tumor immune
response generated by the DC vaccine. However,
to date, limited studies show a correlation between
immune responders and clinical responders, indicating
that either we are not analyzing the right portion of the
immune response or that the mode of action (MOA) of
DC vaccines is not as expected. Chris Schmidt empha-
sized that we should monitor responses to the tumor
and not only to the vaccine and they also observed that
DC from complete responders surprisingly had lower
IL-12p70/IL-10 ratios, which is not conform the stereo-
type of immunogenic DC. Viggo Van Tendeloo and
Massimo Di Nicola reported that higher levels of
activated NK cells correlated with clinical response, indi-
cating that DC vaccines not only act on the T cell
response but also on innate immunity [10,11]. Massimo
Di Nicola used killed autologous tumor cells to load DC
and observed that killed tumor cell preparations from
responding patients showed higher calreticulin and heat
shock protein 90 expression compared to non-respon-
ders, indicating immunogenic tumor cell death is
needed to obtain responses with tumor lysate pulsed
DC [12]. The group of Jolanda de Vries developed a
skin test where the skin-infiltrating lymphocytes (SKILS)
in DTH sites are tested for antigen specificity. The pre-
sence of tumor-specific SKILS correlated with survival
and can thus be used as a predictor of clinical response
[13,14]. Despite the fact that in most studies a correla-
tion between immune response and clinical efficacy
could not be established, Antoni Ribas suggested that, in
future trials, immune monitoring studies need to be
expanded and associated with the observed clinical
responses to assess the underlying immune mechanisms
and the MOA of DC vaccines.
Maximizing DC biology potential
Initial studies on DC vaccination predominantly used
immature or cytokine matured DC. However, since then
several improvements have been developed to enhance
the DC’s capacity to stimulate T cells and even circum-
vent immunosuppression. Bart Neyns presented data
from so-called TriMix DC, i.e. DC transfected with
mRNA encoding constitutively active TLR4 (caTLR4),
CD40L and CD70. These TriMix DC are highly mature
and secrete high levels of IL-12p70. When co-trans-
fected with TAA encoding mRNA, TriMix DC induce
potent TAA-specific CTL in advanced melanoma
patients [15]. CD4+ T cells are essential for the induc-
tion of potent CTL response, but data concerning Th
cell induction by DC vaccines are scarce. Martin Can-
non highlighted that we should try to redirect DC-acti-
vated Treg responses to anti-tumor Th17 responses
since it was shown in ovarian cancer that these 2 cell
types are inversely correlated and that tumor-associated
polyfunctional Th17 cells are associated with improved
clinical outcome [16]. Therefore, they treated DC with
IL-15 and a p38 MAPK inhibitor and these cells are
capable of inducing TNFa+ FoxP3- IL-17 secreting
CD4+ T cells that show reduced PD-1 expression and
tumor-specific CTL. DC treated with IL-15 and p38
MAPK inhibitor show decreased expression of B7-H1
and reduced IDO activity. Scott Pruitt presented data of
local delivery of immune modulators by DC. Therefore,
DC were transfected with RNA encoding the GITRL
fusion protein and/or anti-CTLA4 mAb. These media-
tors are then produced locally by DC, thereby prevent-
ing side effects that occur with systemic administration
as observed with anti-CTLA4 mAb [17]. Previous stu-
dies have shown that injected DC poorly traffic to
lymph nodes where they should interact with T cells.
Jeffrey Weber therefore designed a system to attract
T cells to the injection site and induce in this way and
“artificial lymph nodal aggregate” for T cell priming. To
achieve this, DC are adenovirally transduced with
CCL21/SLC and pulsed with peptides. The trial is still
ongoing, but immunohistochemical analysis of the injec-
tion site shows substantial T cell infiltration. Another
intriguing approach consists of redirecting the immune
response from an anti-tumor response to an anti-viral
response. Dagmar Marx and Volker Schirrmacher
reported studies combining DC with the oncolytic New-
castle Disease Virus (NDV). NDV mediates lysis of
tumor cells, either in vitro to pulse DC with viral onco-
lysates or in vivo to provide a supply of tumor antigens
in the body of the patients. The tumor cells then pre-
sent viral antigens to which a more potent immune
response can be generated since there is less tolerance
and the virus itself also drives DC polarization towards
Th1 inducers [18-21].
Combination strategies
Increasing evidence suggests that DC vaccines on their
own are not capable to induce tumor regression in
a substantial amount of patients, but should instead be
used in combinatorial approaches. Many potential ratio-
nales exist for combination of DC with chemotherapy.
Chemotherapy could have effects on MDSC and/or
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Treg, could increase the susceptibility of tumor cell
apoptosis or lead to increased tumor cell immunogeni-
city, as shown by Angus Dalgleish. He also postulates
that combination with immune response modifiers
like low dose IL-2, Imiquimod or IMiDs would also be
promising. Antoni Ribas showed data from a trial com-
bining DC vaccines with the anti-CTLA4 mAb Tremeli-
mumab, in which 4/16 patients experienced long term
responses [22]. Jolanda de Vries presented data about
the combination of DC vaccines with Daclizumab pre-
treatment to deplete Treg, but although TAA-specific
T cells could be generated, these T cells had impaired
effector functions and the combination did not result in
a significant effect on survival [23]. An attractive idea is
to combine DC vaccines with adoptive T cell transfer,
where DC vaccines could first prime tumor-specific
T cells in vivo, which could subsequently be expanded
ex vivo and then be given back to the patients. This type
of combination was presented by Isabel Poschke and
Gunnar Kvalheim, but studies are still ongoing. This
type of combination is also complicated by the high
costs. Another rationale is to incorporate DC vaccina-
tion in the standard of care (SOC) treatment if available.
Surasak Phuphanich and Stefaan Van Gool presented
results from this approach, with positive effects on
patient survival [4,5,24-26].
Approved immunotherapeutic vaccines
Provenge® or Sipuleucel-T from Dendreon received the
first approval for a cell-based immunotherapy and hence
is an important step in the development of similar stra-
tegies. This therapeutic vaccine was briefly discussed
during the meeting. Historically, this vaccine is categor-
ized as a DC vaccine, although it does not consist of
“pure” DC; hence the term antigen pulsed activated per-
ipheral blood mononuclear cells is probably more cor-
rect. The latest phase III trial demonstrated that the
effect is merely noted on overall survival (4 month sur-
vival benefit), with less evidence of an antitumor effect
(1/341 PR, 3% of patients with 50% PSA decrease). Two
thirds of patients receiving sipuleucel-T developed anti-
body responses, and nearly three fourths had T cell pro-
liferative responses. Survival was improved for patients
who had an antibody response but not for those with a
T cell response. Although these data are encouraging,
they also highlight again that still very little is known
about the real MOA of such immunotherapeutics.
Furthermore, the high cost of such treatments may
impact its use and further development [27,28]. It would
also be very interesting to investigate whether the effect
of Provenge® can be enhanced by combination with
approaches aiming at modulating the immunosuppres-
sive environment.
Discussion
The general discussion of the meeting focused on a few
key questions to rapidly move DC vaccination forward.
The first part of the discussion concentrated on the
discrepancy between proof of principle and proof of effi-
cacy. Most participants agree that the desired endpoint
is clinical activity (OS, PFS, overall response rate) and
that immune monitoring is less important. The main
problem with this point of view is that efficacy data are
difficult to obtain in phase I clinical trials, so a con-
trolled trial would need to be performed. Other vari-
ables that can affect the selection of the desired
endpoint is whether the patient population is homoge-
neous or heterogeneous, whether there is bulk tumor or
minimal residual disease... It is probably best to carefully
select patients and assess safety and MOA in a phase I
trial and then rapidly move to randomized controlled
trials. Alternatively, vaccination could be added to the
SOC and comparative effectiveness research could be
performed. When focusing on the response rate,
responses (CR, PR or even SD) should always be pro-
longed in time. Besides assessing clinical efficacy,
immune monitoring studies are critical to understand
the MOA of DC vaccines and also reporting of vaccine
characteristics remains crucial in this regard.
Another discussion point focused on the question why
clinical data are disappointing. Probably this relates to
our ignorance about the MOA of DC vaccines. Till now,
there are no convincing data about the timing of vacci-
nation, how frequently we need to vaccinate and for
which period of time. Nevertheless, the approval by the
FDA of Provenge®, the first cellular immunotherapeutic,
has paved the way for further development of DC
vaccines and will certainly boost the field further.
Furthermore, we urgently need to get more knowledge
about how to efficiently skew immune responses
towards the desired phenotype for tumor eradication.
Studies to resolve these issues are thus warranted.
Furthermore, the concept that DC vaccines should be
regarded as bystander therapeutics urges us to go ahead
with the rational design of combinatorial approaches
with chemotherapeutic regimens, other immunothera-
peutic regimens aiming at breaking tolerance, immune
response modifiers or targeted therapies (anti-angiogenic
molecules, STAT3 inhibitors,...).
Next, the discussion moved to the issue of patient selec-
tion for inclusion in DC trials. The rationale argues for
inclusion of less advanced patients in which we should
then be able to follow a tumor marker to assess efficacy.
However, is a patient that can mount an immune response
really an end stage patient? Furthermore, it is not ethical
to treat patients with DC vaccines if they can still benefit
from a SOC treatment. Therefore, it was proposed to try
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to integrate DC vaccination in the SOC treatment if avail-
able or try to combine DC vaccination with available treat-
ment approaches. On the other hand, patients should be
carefully selected before inclusion in DC trials to obtain
maximal benefit as possible, based on baseline characteris-
tics that are known to correlate with improved outcome
and on the aggressiveness of the disease progression.
Finally, how can we improve the potential of DC ther-
apy? Ideally, we should move from ex vivo generated
DC to purified myeloid or plasmacytoid DC or even in
vivo DC targeting, but before this can be pursued we
need to better understand the immunoregulatory net-
work. The use of multiple defined antigens or the whole
tumor antigenic spectrum is encouraged to avoid escape
and to induce a broad response, even if this implies the
risk to induce some auto-immune effects, which seems
to be beneficial for DC vaccine efficacy. Furthermore,
studies should focus on the induction of broad poly-
functional immune responses encompassing both innate
and adaptive immunity.
In conclusion, this meeting brought together experts
in different aspects of DC vaccine development and pro-
vided a platform for exchange of ideas, interesting new
findings, encountered barriers and potential innovative
new approaches. Hopefully this cross-fertilization
between scientists will result in the translation to suc-
cessful clinical trials that can move forward the DC vac-
cination approach.
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